Search alternatives:
point decrease » point increase (Expand Search)
web decrease » we decrease (Expand Search), teer decrease (Expand Search), step decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a web » _ web (Expand Search)
Showing 16,621 - 16,640 results of 102,951 for search '(( a web decrease ) OR ( 5 ((point decrease) OR (((mean decrease) OR (a decrease)))) ))', query time: 1.60s Refine Results
  1. 16621
    Sociodemographic and reproductive factors associated with good quality antenatal care.

    Sociodemographic and reproductive factors associated with good quality antenatal care. by Seth Amponsah-Tabi (13949142)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  2. 16622
    Sociodemographic and reproductive characteristics of the study participants.

    Sociodemographic and reproductive characteristics of the study participants. by Seth Amponsah-Tabi (13949142)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  3. 16623
    Comorbidities and severity scales at admission for the different treatment groups.

    Comorbidities and severity scales at admission for the different treatment groups. by Ismael Francisco Aomar-Millán (14838595)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  4. 16624
    S1 Data -

    S1 Data - by Seth Amponsah-Tabi (13949142)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  5. 16625
    Probability of remaining as an inpatient at 30 days in the different treatment groups.

    Probability of remaining as an inpatient at 30 days in the different treatment groups. by Ismael Francisco Aomar-Millán (14838595)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  6. 16626
    Probability of medical discharge at 30 days in the different treatment groups.

    Probability of medical discharge at 30 days in the different treatment groups. by Ismael Francisco Aomar-Millán (14838595)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  7. 16627
    Probability of remaining as an inpatient at 60 days in the different treatment groups.

    Probability of remaining as an inpatient at 60 days in the different treatment groups. by Ismael Francisco Aomar-Millán (14838595)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  8. 16628
    <i>sirB<sup>−</sup></i>, Vic1, Vic2 and T6SS-double mutants showed decreased virulence in planta.

    <i>sirB<sup>−</sup></i>, Vic1, Vic2 and T6SS-double mutants showed decreased virulence in planta. by Johanna Nykyri (124297)

    Published 2012
    Save to List
    Saved in:
  9. 16629
    A BMP7 Variant Inhibits Tumor Angiogenesis <i>In Vitro</i> and <i>In Vivo</i> through Direct Modulation of Endothelial Cell Biology

    A BMP7 Variant Inhibits Tumor Angiogenesis <i>In Vitro</i> and <i>In Vivo</i> through Direct Modulation of Endothelial Cell Biology by Courtney M. Tate (555115)

    Published 2015
    “…Importantly, in an <i>in vivo</i> angiogenic plug assay that serves as a measurement of angiogenesis, BMP7v significantly decreased hemoglobin content indicating inhibition of neoangiogenesis. …”
    Save to List
    Saved in:
  10. 16630
    The residual signaling activity of γ2-MSH and γ3-MSH in plasma is MCR specific and plasma stability decreased compared to CNS stability.

    The residual signaling activity of γ2-MSH and γ3-MSH in plasma is MCR specific and plasma stability decreased compared to CNS stability. by Karin Löw (8805416)

    Published 2020
    Save to List
    Saved in:
  11. 16631
    Supplementary Material for: Somatic variants and exon-level copy number changes in five hyperplastic-stage oral leukoplakias.

    Supplementary Material for: Somatic variants and exon-level copy number changes in five hyperplastic-stage oral leukoplakias. by Anne A. (13992672)

    Published 2023
    “…Oral leukoplakia (OL), an oral potentially malignant disorder begins with a hyperplastic/hyperkeratotic stage at which no genome-scale somatic single nucleotide variant profiles have been described so far. …”
    Save to List
    Saved in:
  12. 16632
    Supplementary Material for: Somatic variants and exon-level copy number changes in five hyperplastic-stage oral leukoplakias.

    Supplementary Material for: Somatic variants and exon-level copy number changes in five hyperplastic-stage oral leukoplakias. by Anne A. (13992672)

    Published 2023
    “…Oral leukoplakia (OL), an oral potentially malignant disorder begins with a hyperplastic/hyperkeratotic stage at which no genome-scale somatic single nucleotide variant profiles have been described so far. …”
    Save to List
    Saved in:
  13. 16633
    Supplementary Material for: Somatic variants and exon-level copy number changes in five hyperplastic-stage oral leukoplakias.

    Supplementary Material for: Somatic variants and exon-level copy number changes in five hyperplastic-stage oral leukoplakias. by Anne A. (13992672)

    Published 2023
    “…Oral leukoplakia (OL), an oral potentially malignant disorder begins with a hyperplastic/hyperkeratotic stage at which no genome-scale somatic single nucleotide variant profiles have been described so far. …”
    Save to List
    Saved in:
  14. 16634
    Supplementary Material for: Somatic variants and exon-level copy number changes in five hyperplastic-stage oral leukoplakias.

    Supplementary Material for: Somatic variants and exon-level copy number changes in five hyperplastic-stage oral leukoplakias. by Anne A. (13992672)

    Published 2023
    “…Oral leukoplakia (OL), an oral potentially malignant disorder begins with a hyperplastic/hyperkeratotic stage at which no genome-scale somatic single nucleotide variant profiles have been described so far. …”
    Save to List
    Saved in:
  15. 16635
    Supplementary Material for: Somatic variants and exon-level copy number changes in five hyperplastic-stage oral leukoplakias.

    Supplementary Material for: Somatic variants and exon-level copy number changes in five hyperplastic-stage oral leukoplakias. by Anne A. (13992672)

    Published 2023
    “…Oral leukoplakia (OL), an oral potentially malignant disorder begins with a hyperplastic/hyperkeratotic stage at which no genome-scale somatic single nucleotide variant profiles have been described so far. …”
    Save to List
    Saved in:
  16. 16636
    Supplementary Material for: Somatic variants and exon-level copy number changes in five hyperplastic-stage oral leukoplakias.

    Supplementary Material for: Somatic variants and exon-level copy number changes in five hyperplastic-stage oral leukoplakias. by Anne A. (13992672)

    Published 2023
    “…Oral leukoplakia (OL), an oral potentially malignant disorder begins with a hyperplastic/hyperkeratotic stage at which no genome-scale somatic single nucleotide variant profiles have been described so far. …”
    Save to List
    Saved in:
  17. 16637
    Supplementary Material for: Somatic variants and exon-level copy number changes in five hyperplastic-stage oral leukoplakias.

    Supplementary Material for: Somatic variants and exon-level copy number changes in five hyperplastic-stage oral leukoplakias. by Anne A. (13992672)

    Published 2023
    “…Oral leukoplakia (OL), an oral potentially malignant disorder begins with a hyperplastic/hyperkeratotic stage at which no genome-scale somatic single nucleotide variant profiles have been described so far. …”
    Save to List
    Saved in:
  18. 16638
    BMDCs produce decreased amounts of IL-23 and IL-6 and become poor stimulators for Th17 after exposure to oxATP in culture.

    BMDCs produce decreased amounts of IL-23 and IL-6 and become poor stimulators for Th17 after exposure to oxATP in culture. by Ronglan Zhao (658986)

    Published 2016
    Save to List
    Saved in:
  19. 16639
    Metformin is effective against ERα<sup>-</sup> and ERα<sup>+</sup> breast cancer cells, and decreases ERα levels.

    Metformin is effective against ERα<sup>-</sup> and ERα<sup>+</sup> breast cancer cells, and decreases ERα levels. by Gerald Davies (4666435)

    Published 2017
    Save to List
    Saved in:
  20. 16640
    Fig 4 -

    Fig 4 - by Viktorija Preitakaitė (17508980)

    Published 2023
    Save to List
    Saved in:

Search Tools: